WASHINGTON— Congressman Markwayne Mullin (OK-02) offered an amendment that would create value-based payment models for gene therapies to H.R. 3 during the Energy and Commerce Committee markup. The amendment was withdrawn.
“We have the ability to cure patients who struggle with debilitating diseases like cancer, heart disorders, hemophilia, and sickle cell disease with one treatment,” Mullin said during the markup. “Drug developers are taking extraordinary risks to invest in these groundbreaking therapies, which could easily cost millions of dollars per patient once they reach the market. These cures are in the drug approval pipeline and coming to the market, but without an affordable way for consumers to pay for them it will be hard for patients to access them. Policy must catch up with the science. Instead of stifling innovation and competition by price setting, let’s start paying for value.”
Gene therapies are defined as one-time use, potentially curative treatments.
Since they are only used once, they are expensive for patients and can be difficult for insurers to.
There are currently two gene therapies approved by the FDA with dozens more in the drug approval pipeline.